You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 31, 2012

Country Overview: Medical Devices in Thailand

Journal of Medical Device Regulation

Reproduced with the kind permission of Global Regulatory Press from the Journal of Medical Device Regulation, 2012, 9(3), 83-89 (www.globalregulatorypress.com).

Introduction

Now more than ever, the benefits and importance of healthcare have become more evident to Thai citizens. With the emergence of extensive research and development, rapidly advancing medical technology, and an overall improvement in awareness and education in the relevant field of law, the Thai population demands better standards of regulatory enforcement, an improvement in medical device provision and thus, in the long run, an overall increase in life expectancy.

Market research carried out in 2010 showed that the value of medical equipment imported into Thailand amounted to over THB 25 billion (around US$ 853 million) that year. The research also projected a likely average increase of 9% per year, or to THB 38 billion (around US$ 1.3 billion) in 2015.

Regulatory authority

In order to manufacture, import or sell a medical device in Thailand, it is crucial for medical device companies (manufacturers, importers and sellers) to understand fully the applicable local regulations. These are controlled by the Medical Device Control Division (MDCD) of the Thai Food and Drug Administration (TFDA).

Thai Food and Drug Administration, Ministry of Public Health
Medical Devices Control Division
Tiwanon Road, Nontaburi, Thailand
Tel: 66-2590-7244, 66-2590-7247, 66-2590-7249
Fax: 66-2591-8479, 66-2591-8480
E-mail: [email protected]

Legislative framework

The MDCD regulates and monitors the quality, standards, efficiency and safety of medical devices that are manufactured, imported and sold in Thailand, in accordance with the Medical Device Act of 2008 (B.E. 2551), related Ministerial Regulations, and Notices of the Ministry of Public Health. Important Ministerial Regulations are:

  • No. 1 B.E. 2533 (A.D. 1990), License for production – application requirements;
  • No. 2 B.E. 2533 (A.D. 1990), License for importation – application requirements;
  • No. 3 B.E. 2533 (A.D. 1990), License for distribution – application requirements;
  • No. 4 B.E. 2533 (A.D. 1990), Production, importation or distribution of notification medical devices;
  • B.E. 2552 (A.D. 2009), Fees for medical devices;
  • B.E. 2552 (A.D. 2009), Terms and conditions for registering a place of business for medical device production;
  • B.E. 2552 (A.D. 2009), Terms and conditions for registering a place of business for medical device importation.

Copies of the Medical Device Act of 2008 and all the Ministerial regulations may be accessed (in Thai) via the Government Gazette’s database (http://61.19.241.70/rkjnew/Front/ShowList.aspx?LawGroupID=53123&rkjTypeID=1).

Pre-approval of all medical devices is required before any commercial activity begins. It is also important to note that only locally established companies can import and register medical devices in Thailand.

Regulatory controls

Definition of a medical device

Contrary to popular belief, the definition of a medical device under Thai law is very similar to, and combines elements of, both the definitions used in the USA and the European Union (EU). The only difference is that the EU definition is narrower, as it is more detailed and excludes medical devices for animals, while the US definition does not include software. Section 4 of the Medical Device Act of 2008 defines medical devices as:

“(1) Instruments, apparatus, implements, machines, appliances, implants, in vitro reagents or calibrators, software, material or other similar or related articles, intended by the producer to be used alone, or in combination, for human beings or animals for one or more of the following specific purpose(s):

(a) Performing treatment in the medical profession, the nursing and midwifery profession, the dentistry profession, the medical technology profession, the physical therapy profession, and the veterinary profession, as prescribed by legislation related to performing other medical professions and public health as prescribed by the Minister;

(b) Diagnosing, preventing, monitoring, treating or alleviating disease in humans or animals;

(c) Diagnosing, monitoring, treating, alleviating or compensating for an injury to a human or an animal;

(d) Investigating, replacing, modifying or supporting the anatomy or the physiological process of the human body or in an animal;

(e) Supporting or sustaining the life of a human or animal;

(f) Controlling conception or helping with reproduction in a human or an animal;

(g) Helping, or helping to compensate for,a disability or infirmity in a human or an animal;

(h) Providing information for medical or diagnostic purposes, by means of an in vitro examination of specimens derived from the body of a human or an animal; and

(i) Destroying or disinfecting a medical device.

(2) Accessories or constituents in the instruments, appliances, machines, products, or articles under (1);

(3) Instruments, apparatus, machines, products or other articles prescribed by the Minister as a medical device.

Any of the outcomes as stipulated in the statement in (1), as they occur in a human body or animal, must not be derived from any pharmacology, immunology, or oxidation reaction aimed at creating energy as its main element.”

Classification

When introducing new products to the Thai market, many importers have important concerns about product classification. This is particularly because of the rapid pace of technological progress, which has advanced beyond the current TFDA regulations relating to medical devices. In addition, medical devices are complex and have many uses and benefits. Therefore, some medical devices, which are classified as such in other countries, may not necessarily be classified as medical devices in Thailand.

Although many countries rely on the US or EU classification systems, Thailand uses a different type of classification. Companies need to be aware that Thai classifications may be more or less stringent than their US/EU counterparts.

In Thailand, medical devices are classified into three classes based on the level of risk associated with the use of the device. This is a local Thai regulatory classification system, which appears to be applied in reverse order compared with the US/EU classification systems. The TFDA subjects Class III devices to the least stringent controls, and Class I devices to the most stringent controls.

Class I – Licensed Medical Devices

A Licensed Medical Device is the most strictly controlled class. Class I devices are usually those that support human life, are of substantial importance in preventing the impairment of human health, or prevent a potential or unreasonable risk of illness or injury. Examples of these devices include condoms, examination gloves, surgical gloves, contact lenses, and human immunodeficiency virus (HIV) test kits (for in vitro diagnostic use).

The Licensed Medical Device category requires the most information to be submitted for approval including, but not limited to, a Certificate of Analysis from the Department of Medical Sciences (DMSc), stability data, clinical study and/or evaluation data, a mandatory Thai label and leaflet, product formulae, and production processes. Such medical devices must meet the quality standards set out in the Notice of the Ministry of Public Health for each type of medical device.

Class II – Notification Medical Devices

A Notification Medical Device is subject to a less intensive review procedure than a Licensed Medical Device. As the name implies, the TFDA must be notified of Class II devices. Examples of Notification Medical Devices include HIV test kits (for investigational use and for research use), physical therapy products, alcohol detectors, implanted silicone breast prostheses, and equipment or instruments typically used for breast enhancement.

The information requirements for Notification Medical Devices are the same as those applicable for a Licensed Medical Device, except for some requirements such as the test results from the DMSc.

Class III – General Medical Devices

The requirements for General Medical Devices are the least stringent. Only the product description/information, product catalogue, and the Certificate of Free Sale need to be submitted to the TFDA for approval prior to marketing in Thailand. For some General Medical Devices, such as sterile products and laser equipment products, an ISO 13485 Certificate and technical data specifications are also necessary for approval.

Borderline products

Sometimes a healthcare product may overlap with, or be on the borderline between, the medical device, pharmaceutical and cosmetics legislation. If an applicant wishes to ensure that a product can be classified as a medical device under the Medical Device Act of 2008, the applicant may ask the TFDA to assess the product classification. The original documents from a manufacturer of the product which are required for the TFDA’s consideration are as follows:

  • details of the product (product name, the name and address of the manufacturer, product description, principle of operation/ mechanism, component material of the product, product specification, intended uses and indications, and instructions for use);
  • product catalogue;
  • product leaflet; and
  • supporting academic documents and/or government certificates from the manufacturing country showing the controlled status of the product (if needed).

The timeframe for the product classification process is officially 10 working days. However, for some difficult cases, the TFDA will need to forward the case to the Medical Device Committee for their consideration and determination. This additional review process may take more time.

Examples of differing classifications

Dermal fillers provide a good example of how the classification system in Thailand differs from other jurisdictions. Dermal fillers are considered to be Class IIb medical devices (generally regarded as medium risk) in the EU, and Class III (pre-market approval) in the USA. However, in Thailand, as of today, such products are still considered to be drugs. Thus, the process will be more stringent and, depending on the category, the requirements may be more burdensome, especially since companies would not necessarily be able to provide the quality, clinical and non-clinical parts required for new drugs, in accordance with the Association of Southeast Asian Nations (ASEAN) guidelines.

A similar problem exists for blood bag systems, which are currently classified as drugs in Thailand. The TFDA does not take into consideration the product (the bag) itself, but rather the component in the bag (blood) that is provided to the patient; it is this factor that determines the classification. However, the TFDA is in the process of adopting a new regulation that will classify blood bag systems as medical devices. This regulation is expected to be implemented in the near future.

Finally, products such as exercise machines used in hospitals may be classified as medical devices in Thailand, even though they are not classified as such in the USA/EU. This classification decision will depend on the intended use of the products as specified in the relevant product leaflets.

Advertising

It is mandatory to obtain an advertising license before undertaking any type of advertising or promotion for a medical device.

The concept of advertising has evolved over the past few decades. It no longer merely covers print materials such as publications, brochures, posters, or even television and radio advertisements. Today, online marketing of medical devices is also controlled in Thailand, especially via social networks or blogs.

Advertising must meet TFDA information requirements. For example, it must contain the name of the medical device, TFDA mandatory warnings, and the name of the importer and/or manufacturer. Information distributed on the Internet that is intended for customers or patients in Thailand must also meet these requirements.

The TFDA will review and consider the advertising application before issuing a license. According to Clause 7, Section 59 of the Medical Device Act of 2008, advertisements of medical devices must not:

  • show benefits, quality, volume, standard, components or the origin of the medical device, in a false or misleading manner;
  • show guarantee of benefits or endorsements by any person;
  • offer monetary compensation, or any other reward to patients, for the use of a medical device on a trial basis;
  • show benefits in respect of preventing, treating, mitigating or the healing of a disease or symptom, which the TFDA prohibits from being advertised; and
  • show any statements that may cause misunderstanding, in material part, in respect to the medical device.

Examples of words that cannot be used in medical device advertisements in Thailand are ‘excellent’, ‘special’, ‘the best’, ‘completely cured’, ‘holy’, ‘marvelous’, ‘safe’, ‘number one’, ‘no adverse effects’, ‘superior’, ‘most appropriate’, etc. These are some of the most well-known words that are prohibited. In order to determine whether particular words or phrases are acceptable, it is necessary to consider the use of the products themselves, and the construction of the messages.

When a license number has been obtained, it must be included in the advertisement. It is also important to note that an advertising license for a medical device is only valid for a period of three years from the date of issue.

Vigilance requirements

According to the Medical Device Act of 2008, Section 41(4), the registrant of the establishment, licensee, or notifier has to prepare a report on the abnormal performance or any adverse reactions of the medical device, and a report on its correction to the licensor, whether it happened in the country or abroad. However, it shall be made in accordance with the rules, procedures, and conditions prescribed by the Minister. Currently, there is no specific regulation under this Act. Therefore, the Ministerial Regulation No. 5 B.E. 2533 (A.D. 1990) on production, importation, and distribution report requirements should be followed.

The licensed and notified producer, importer, or distributor must submit an adverse event report in the event that the licensed and notified producer, importer, or distributor discovers an adverse event associated with the medical device. A report of the incident is required to be submitted to the Secretary General of the TFDA within 15 working days. In addition, if the adverse event is serious or causes death, it must be reported within 24 hours from the time the licensed and notified producer, importer, or distributor discovers such an adverse event.

Post-market surveillance

In order to ensure that companies comply with both the TFDA regulations and the advertisement requirements for medical devices, the TFDA conducts random post-marketing audits of companies.

Before product launch, the TFDA conducts a pre-marketing review, and it is highly protective of Thai consumers. As a developing country, Thai consumers rely heavily on the government to protect them. This is quite different from the practice in the USA, where product liability cases and class actions are often filed, which serves to deter companies from marketing harmful products. As part of its post-marketing reviews, the TFDA collaborates with other agencies, including the DMSc and provincial health offices, to monitor, inspect and follow up on pre-marketing controls.

According to the MDCD’s website, the main purposes for undertaking post-marketing audits are:

  • to protect the quality, safety and efficiency of medical devices for Thai people;
  • to monitor and follow up on trading, and indicate improper trends relating to medical devices;
  • to identify and punish whoever breaks the relevant medical device laws or regulations; and
  • to protect and persuade entrepreneurs to operate a legal business, and promote fair competition.

All registered medical device entrepreneurs also have mandatory duties to record and prepare a report for TFDA inspection relating to the quantities of medical devices manufactured, imported and sold in the Thai market, for a period of not less than five years from the manufacturing, importation or sales dates, and not less than one year from the expiry dates (if any). This requirement is set forth in the Notification of the Ministry of Public Health on the terms and conditions for the preparation of records, and for manufacturing, importing and selling reports, which has been effective since 7 February 2012.

All product registration holders also have to prepare and submit an annual report in respect of manufacturing, importing or selling medical devices, according to the TFDA’s report forms, as mentioned in the above Notification.

If a company does not comply with the TFDA requirements, the penalties are imprisonment not exceeding six months, or a fine not exceeding THB 50,000 (around US$1705), or both.

In practice, the TFDA has rarely issued public punishments for non-compliance in respect to advertising licenses. However, companies need to be aware that random audits still occur. If inspected, employees should report the inspection immediately to their supervisors, prior to agreeing to sign any report from the TFDA.

Clinical trial requirements

There are no specific regulations on clinical trials in Thailand. Thus, no clinical trial requirements are specifically tailored for medical devices. For clinical trials in general, the government relies on the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practices Guidelines.

Labeling and language requirements

According to the Medical Device Act of 2008, section 44, the registrant of an establishment, licensee, or notifier who produces or imports medical devices shall provide a label and its accompanying document. This document should not include any false statement or overstate the truth.

However, the specific requirements for labels and/or accompanying documents (e.g., product leaflet) for each type of medical device are different. The requirements in regard to the label and/or leaflet for Licensed Medical Devices and Notified Medical Devices are mentioned in the Notification of Ministry of Public Health for each medical device.

Currently, there are no specific labeling requirements for General Medical Devices. However, the TFDA has announced a draft regulation on this matter.

Future changes

Thailand and the other nine ASEAN Member States are moving toward implementation of the ASEAN Economic Community (AEC) in 2015. The formation of a single market and a single production base in the region will permit companies within the AEC to move their capital freely, and will serve to break down effectively existing trade barriers that currently stunt intra-regional trade within the 10-member trading bloc.

The implementation of consistent standards within the ASEAN countries for each product, including related rules and regulations that conform to international standards, will in theory ensure the removal of trade barriers or obstacles. This process has already started for drugs and cosmetics.

With regard to the harmonization rules for medical devices, each ASEAN Member State has until 2014 to implement the new requirements established by the Medical Device Working Group, and to finalize the harmonization process for all medical devices. This includes formulating a common definition for medical devices (derived from the Global Harmonization Task Force definition), harmonizing the classification of products (five classes based on the assessed risk of the products), formulating a common list of international medical device standards in order to obtain similar quality assurance, and implementing a Common Submission Dossier Template (CSDT), among other requirements.

The TFDA has announced that is considering using the CSDT by 2012-2013, and preparations are underway for the implementation of the ASEAN Medical Device Directive within the next two years. Additionally, the TFDA is currently forcing local manufacturers to obtain Good Manufacturing Practice Certificates for their facilities, which are equivalent to international ISO 13485 certificates, for example.

RELATED INSIGHTS​ 

July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements